 |
2 Diseases |  |
32 Trials |
|
32 Trials |  |
1662 News |  |
| «12...1314151617181920212223...2425» |
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Prophylaxis and the Effect on Cytomegalovirus (CMV) Infection () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2842;
Letermovir prophylaxis is associated with lower risk for CMV infection requiring treatment compared to no prophylaxis. The reduced incidence of CMV infection resulted in decreased hospital admissions, length of stay, and use of expensive anti-CMV therapy, which correlated to an estimated cost savings of $85,032.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Prophylaxis and the Effect on Cytomegalovirus (CMV) Infection () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2841;
Letermovir prophylaxis is associated with lower risk for CMV infection requiring treatment compared to no prophylaxis. The reduced incidence of CMV infection resulted in decreased hospital admissions, length of stay, and use of expensive anti-CMV therapy, which correlated to an estimated cost savings of $85,032.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Prophylaxis and the Effect on Cytomegalovirus (CMV) Infection () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2840;
Letermovir prophylaxis is associated with lower risk for CMV infection requiring treatment compared to no prophylaxis. The reduced incidence of CMV infection resulted in decreased hospital admissions, length of stay, and use of expensive anti-CMV therapy, which correlated to an estimated cost savings of $85,032.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Prophylaxis and the Effect on Cytomegalovirus (CMV) Infection () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2839;
Letermovir prophylaxis is associated with lower risk for CMV infection requiring treatment compared to no prophylaxis. The reduced incidence of CMV infection resulted in decreased hospital admissions, length of stay, and use of expensive anti-CMV therapy, which correlated to an estimated cost savings of $85,032.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Prophylaxis and the Effect on Cytomegalovirus (CMV) Infection () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2838;
Letermovir prophylaxis is associated with lower risk for CMV infection requiring treatment compared to no prophylaxis. The reduced incidence of CMV infection resulted in decreased hospital admissions, length of stay, and use of expensive anti-CMV therapy, which correlated to an estimated cost savings of $85,032.
- Prevymis (letermovir) / Merck (MSD), Campath (alemtuzumab) / Sanofi
[VIRTUAL] Efficacy of Letermovir for CMV Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplant T-Cell Depleted with Alemtuzumab. () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2302;
The reduced incidence of CMV infection resulted in decreased hospital admissions, length of stay, and use of expensive anti-CMV therapy, which correlated to an estimated cost savings of $85,032. LTV was found to meaningfully decrease the rate of clinically significant CMV infection in high risk patients undergoing TCD HSCT and was overall well tolerated.
- Prevymis (letermovir) / Merck (MSD), Campath (alemtuzumab) / Sanofi
[VIRTUAL] Efficacy of Letermovir for CMV Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplant T-Cell Depleted with Alemtuzumab. () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2301;
LTV was found to meaningfully decrease the rate of clinically significant CMV infection in high risk patients undergoing TCD HSCT and was overall well tolerated. LTV was found to meaningfully decrease the rate of clinically significant CMV infection in high risk patients undergoing TCD HSCT and was overall well tolerated.
- Prevymis (letermovir) / Merck (MSD), Campath (alemtuzumab) / Sanofi
[VIRTUAL] Efficacy of Letermovir for CMV Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplant T-Cell Depleted with Alemtuzumab. () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2300;
LTV was found to meaningfully decrease the rate of clinically significant CMV infection in high risk patients undergoing TCD HSCT and was overall well tolerated. LTV was found to meaningfully decrease the rate of clinically significant CMV infection in high risk patients undergoing TCD HSCT and was overall well tolerated.
- Prevymis (letermovir) / Merck (MSD), Campath (alemtuzumab) / Sanofi
[VIRTUAL] Efficacy of Letermovir for CMV Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplant T-Cell Depleted with Alemtuzumab. () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2299;
LTV was found to meaningfully decrease the rate of clinically significant CMV infection in high risk patients undergoing TCD HSCT and was overall well tolerated. LTV was found to meaningfully decrease the rate of clinically significant CMV infection in high risk patients undergoing TCD HSCT and was overall well tolerated.
- Prevymis (letermovir) / Merck (MSD), Campath (alemtuzumab) / Sanofi
[VIRTUAL] Efficacy of Letermovir for CMV Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplant T-Cell Depleted with Alemtuzumab. () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2298;
LTV was found to meaningfully decrease the rate of clinically significant CMV infection in high risk patients undergoing TCD HSCT and was overall well tolerated. LTV was found to meaningfully decrease the rate of clinically significant CMV infection in high risk patients undergoing TCD HSCT and was overall well tolerated.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Prophylaxis Outcomes in Allogeneic Hematopoietic Cell Transplant Recipients () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2292;
LTV prophylaxis in the first 100 days of HCT decreased the risk of CMV reactivation. LTV prophylaxis did not impact time-to-engraftment post alloHCT.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Prophylaxis Outcomes in Allogeneic Hematopoietic Cell Transplant Recipients () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2291;
LTV prophylaxis in the first 100 days of HCT decreased the risk of CMV reactivation. LTV prophylaxis did not impact time-to-engraftment post alloHCT.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Prophylaxis Outcomes in Allogeneic Hematopoietic Cell Transplant Recipients () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2290;
LTV prophylaxis in the first 100 days of HCT decreased the risk of CMV reactivation. LTV prophylaxis did not impact time-to-engraftment post alloHCT.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Prophylaxis Outcomes in Allogeneic Hematopoietic Cell Transplant Recipients () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2289;
LTV prophylaxis in the first 100 days of HCT decreased the risk of CMV reactivation. LTV prophylaxis did not impact time-to-engraftment post alloHCT.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Prophylaxis Outcomes in Allogeneic Hematopoietic Cell Transplant Recipients () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2288;
LTV prophylaxis in the first 100 days of HCT decreased the risk of CMV reactivation. LTV prophylaxis did not impact time-to-engraftment post alloHCT.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] HLA Genotype Is Associated with Cytomegalovirus Reactivation in Pediatric Allogeneic Hematopoietic Cell Transplant () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2272;
Pediatric recipients of allo HCT with HLA genotypes previously defined as advantageous by HLA restriction of CMV CTL therapy were significantly less likely to reactivate CMV. These findings indicate that specific HLA molecules are superior at presenting CMV peptides for adaptive immune response in allo HCT pts and illustrate prognostic implications for donor selection.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] HLA Genotype Is Associated with Cytomegalovirus Reactivation in Pediatric Allogeneic Hematopoietic Cell Transplant () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2271;
Pediatric recipients of allo HCT with HLA genotypes previously defined as advantageous by HLA restriction of CMV CTL therapy were significantly less likely to reactivate CMV. These findings indicate that specific HLA molecules are superior at presenting CMV peptides for adaptive immune response in allo HCT pts and illustrate prognostic implications for donor selection.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] HLA Genotype Is Associated with Cytomegalovirus Reactivation in Pediatric Allogeneic Hematopoietic Cell Transplant () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2270;
Pediatric recipients of allo HCT with HLA genotypes previously defined as advantageous by HLA restriction of CMV CTL therapy were significantly less likely to reactivate CMV. These findings indicate that specific HLA molecules are superior at presenting CMV peptides for adaptive immune response in allo HCT pts and illustrate prognostic implications for donor selection.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] HLA Genotype Is Associated with Cytomegalovirus Reactivation in Pediatric Allogeneic Hematopoietic Cell Transplant () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2269;
Pediatric recipients of allo HCT with HLA genotypes previously defined as advantageous by HLA restriction of CMV CTL therapy were significantly less likely to reactivate CMV. These findings indicate that specific HLA molecules are superior at presenting CMV peptides for adaptive immune response in allo HCT pts and illustrate prognostic implications for donor selection.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] HLA Genotype Is Associated with Cytomegalovirus Reactivation in Pediatric Allogeneic Hematopoietic Cell Transplant () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2268;
Pediatric recipients of allo HCT with HLA genotypes previously defined as advantageous by HLA restriction of CMV CTL therapy were significantly less likely to reactivate CMV. These findings indicate that specific HLA molecules are superior at presenting CMV peptides for adaptive immune response in allo HCT pts and illustrate prognostic implications for donor selection.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] CMV-Specific Cell-Mediated Immune Reconstitution during Letermovir Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2207;
4.5% of CMV R+ participants had no CMV CMI response pre-HCT, consistently lacked CMV CMI response post-HCT and did not reactivate CMV, indicating that patients may be falsely characterized by CMV antibody assay. CMV CMI assays rather than CMV serologies pre-HCT may be a useful tool to guide risk stratification for CMV monitoring and letermovir usage.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] CMV-Specific Cell-Mediated Immune Reconstitution during Letermovir Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2206;
4.5% of CMV R+ participants had no CMV CMI response pre-HCT, consistently lacked CMV CMI response post-HCT and did not reactivate CMV, indicating that patients may be falsely characterized by CMV antibody assay. CMV CMI assays rather than CMV serologies pre-HCT may be a useful tool to guide risk stratification for CMV monitoring and letermovir usage.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] CMV-Specific Cell-Mediated Immune Reconstitution during Letermovir Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2205;
4.5% of CMV R+ participants had no CMV CMI response pre-HCT, consistently lacked CMV CMI response post-HCT and did not reactivate CMV, indicating that patients may be falsely characterized by CMV antibody assay. CMV CMI assays rather than CMV serologies pre-HCT may be a useful tool to guide risk stratification for CMV monitoring and letermovir usage.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] CMV-Specific Cell-Mediated Immune Reconstitution during Letermovir Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2204;
4.5% of CMV R+ participants had no CMV CMI response pre-HCT, consistently lacked CMV CMI response post-HCT and did not reactivate CMV, indicating that patients may be falsely characterized by CMV antibody assay. CMV CMI assays rather than CMV serologies pre-HCT may be a useful tool to guide risk stratification for CMV monitoring and letermovir usage.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] CMV-Specific Cell-Mediated Immune Reconstitution during Letermovir Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2203;
4.5% of CMV R+ participants had no CMV CMI response pre-HCT, consistently lacked CMV CMI response post-HCT and did not reactivate CMV, indicating that patients may be falsely characterized by CMV antibody assay. CMV CMI assays rather than CMV serologies pre-HCT may be a useful tool to guide risk stratification for CMV monitoring and letermovir usage.
- valacyclovir / Generic mfg., acyclovir / Generic mfg.
[VIRTUAL] Effect of High Dose Valacyclovir Versus Standard Dose Acyclovir on HHV-6 after Umbilical Cord Blood Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2202;
The benefits of reducing CSI due to HHV-6 and CMV are well recognized. We are now studying the efficacy of the combination of LET + high dose VAL as prophylaxis in UCB patients.
- valacyclovir / Generic mfg., acyclovir / Generic mfg.
[VIRTUAL] Effect of High Dose Valacyclovir Versus Standard Dose Acyclovir on HHV-6 after Umbilical Cord Blood Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2201;
The benefits of reducing CSI due to HHV-6 and CMV are well recognized. We are now studying the efficacy of the combination of LET + high dose VAL as prophylaxis in UCB patients.
- valacyclovir / Generic mfg., acyclovir / Generic mfg.
[VIRTUAL] Effect of High Dose Valacyclovir Versus Standard Dose Acyclovir on HHV-6 after Umbilical Cord Blood Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2200;
The benefits of reducing CSI due to HHV-6 and CMV are well recognized. We are now studying the efficacy of the combination of LET + high dose VAL as prophylaxis in UCB patients.
- valacyclovir / Generic mfg., acyclovir / Generic mfg.
[VIRTUAL] Effect of High Dose Valacyclovir Versus Standard Dose Acyclovir on HHV-6 after Umbilical Cord Blood Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2199;
The benefits of reducing CSI due to HHV-6 and CMV are well recognized. We are now studying the efficacy of the combination of LET + high dose VAL as prophylaxis in UCB patients.
- valacyclovir / Generic mfg., acyclovir / Generic mfg.
[VIRTUAL] Effect of High Dose Valacyclovir Versus Standard Dose Acyclovir on HHV-6 after Umbilical Cord Blood Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2198;
The benefits of reducing CSI due to HHV-6 and CMV are well recognized. We are now studying the efficacy of the combination of LET + high dose VAL as prophylaxis in UCB patients.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Lower Incidence of Cytomegalovirus Infection in Post-Transplant Cyclophosphamide HLA Mismatched Unrelated Donor Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2192;
Despite more profound lymphopenia on day 30, compared to other modalities, PTCy MMUD transplantation was associated with lower incidence of CMV and cs-CMVi, that seemed independent on the use of CMV prophylaxis; and resulted in lower infection-attributable mortality rates. Larger cohort studies and deep functional immunophenotyping of virus-specific T cells to further assess susceptibility to infection in these populations are needed.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Lower Incidence of Cytomegalovirus Infection in Post-Transplant Cyclophosphamide HLA Mismatched Unrelated Donor Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2191;
Despite more profound lymphopenia on day 30, compared to other modalities, PTCy MMUD transplantation was associated with lower incidence of CMV and cs-CMVi, that seemed independent on the use of CMV prophylaxis; and resulted in lower infection-attributable mortality rates. Larger cohort studies and deep functional immunophenotyping of virus-specific T cells to further assess susceptibility to infection in these populations are needed.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Lower Incidence of Cytomegalovirus Infection in Post-Transplant Cyclophosphamide HLA Mismatched Unrelated Donor Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2190;
Despite more profound lymphopenia on day 30, compared to other modalities, PTCy MMUD transplantation was associated with lower incidence of CMV and cs-CMVi, that seemed independent on the use of CMV prophylaxis; and resulted in lower infection-attributable mortality rates. Larger cohort studies and deep functional immunophenotyping of virus-specific T cells to further assess susceptibility to infection in these populations are needed.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Lower Incidence of Cytomegalovirus Infection in Post-Transplant Cyclophosphamide HLA Mismatched Unrelated Donor Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2189;
Despite more profound lymphopenia on day 30, compared to other modalities, PTCy MMUD transplantation was associated with lower incidence of CMV and cs-CMVi, that seemed independent on the use of CMV prophylaxis; and resulted in lower infection-attributable mortality rates. Larger cohort studies and deep functional immunophenotyping of virus-specific T cells to further assess susceptibility to infection in these populations are needed.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Lower Incidence of Cytomegalovirus Infection in Post-Transplant Cyclophosphamide HLA Mismatched Unrelated Donor Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2188;
Despite more profound lymphopenia on day 30, compared to other modalities, PTCy MMUD transplantation was associated with lower incidence of CMV and cs-CMVi, that seemed independent on the use of CMV prophylaxis; and resulted in lower infection-attributable mortality rates. Larger cohort studies and deep functional immunophenotyping of virus-specific T cells to further assess susceptibility to infection in these populations are needed.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Real-World Experience Using Letermovir for CMV Prophylaxis in High-Risk Allogeneic Hematopoietic Stem Cell Patients in the Setting of Using T-Cell Depletion As Gvhd Prophylaxis and the Impact on CMV Reactivation, 1-Year Overall Survival, and 1-Year Gvhd-Free-Relapse-Free Survival () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2177;
All secondary end-points were similar between both groups, despite increased usage of myeloablative conditioning overall and more high-risk patients in the letermovir group, indicating improved 1-year OS, TRM, and GRFS compared with historical outcomes. Although the secondary end-points were not statistically significant, it may be clinically meaningful, as our center has demonstrated similar outcomes amongst those who were high-risk and received letermovir and those who were low-risk and did not.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Real-World Experience Using Letermovir for CMV Prophylaxis in High-Risk Allogeneic Hematopoietic Stem Cell Patients in the Setting of Using T-Cell Depletion As Gvhd Prophylaxis and the Impact on CMV Reactivation, 1-Year Overall Survival, and 1-Year Gvhd-Free-Relapse-Free Survival () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2176;
All secondary end-points were similar between both groups, despite increased usage of myeloablative conditioning overall and more high-risk patients in the letermovir group, indicating improved 1-year OS, TRM, and GRFS compared with historical outcomes. Although the secondary end-points were not statistically significant, it may be clinically meaningful, as our center has demonstrated similar outcomes amongst those who were high-risk and received letermovir and those who were low-risk and did not.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Real-World Experience Using Letermovir for CMV Prophylaxis in High-Risk Allogeneic Hematopoietic Stem Cell Patients in the Setting of Using T-Cell Depletion As Gvhd Prophylaxis and the Impact on CMV Reactivation, 1-Year Overall Survival, and 1-Year Gvhd-Free-Relapse-Free Survival () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2175;
All secondary end-points were similar between both groups, despite increased usage of myeloablative conditioning overall and more high-risk patients in the letermovir group, indicating improved 1-year OS, TRM, and GRFS compared with historical outcomes. Although the secondary end-points were not statistically significant, it may be clinically meaningful, as our center has demonstrated similar outcomes amongst those who were high-risk and received letermovir and those who were low-risk and did not.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Real-World Experience Using Letermovir for CMV Prophylaxis in High-Risk Allogeneic Hematopoietic Stem Cell Patients in the Setting of Using T-Cell Depletion As Gvhd Prophylaxis and the Impact on CMV Reactivation, 1-Year Overall Survival, and 1-Year Gvhd-Free-Relapse-Free Survival () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2174;
All secondary end-points were similar between both groups, despite increased usage of myeloablative conditioning overall and more high-risk patients in the letermovir group, indicating improved 1-year OS, TRM, and GRFS compared with historical outcomes. Although the secondary end-points were not statistically significant, it may be clinically meaningful, as our center has demonstrated similar outcomes amongst those who were high-risk and received letermovir and those who were low-risk and did not.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Real-World Experience Using Letermovir for CMV Prophylaxis in High-Risk Allogeneic Hematopoietic Stem Cell Patients in the Setting of Using T-Cell Depletion As Gvhd Prophylaxis and the Impact on CMV Reactivation, 1-Year Overall Survival, and 1-Year Gvhd-Free-Relapse-Free Survival () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2173;
All secondary end-points were similar between both groups, despite increased usage of myeloablative conditioning overall and more high-risk patients in the letermovir group, indicating improved 1-year OS, TRM, and GRFS compared with historical outcomes. Although the secondary end-points were not statistically significant, it may be clinically meaningful, as our center has demonstrated similar outcomes amongst those who were high-risk and received letermovir and those who were low-risk and did not.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Use in Patients with Relapsed or Refractory Hematological Malignancies () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2162;
Although the secondary end-points were not statistically significant, it may be clinically meaningful, as our center has demonstrated similar outcomes amongst those who were high-risk and received letermovir and those who were low-risk and did not. The use of letermovir for prevention of CMV infections in patients with relapsed or refractory hematological malignancies, including CAR T cell recipients, should be determined in future trials.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Use in Patients with Relapsed or Refractory Hematological Malignancies () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2161;
The use of letermovir for prevention of CMV infections in patients with relapsed or refractory hematological malignancies, including CAR T cell recipients, should be determined in future trials. The use of letermovir for prevention of CMV infections in patients with relapsed or refractory hematological malignancies, including CAR T cell recipients, should be determined in future trials.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Use in Patients with Relapsed or Refractory Hematological Malignancies () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2160;
The use of letermovir for prevention of CMV infections in patients with relapsed or refractory hematological malignancies, including CAR T cell recipients, should be determined in future trials. The use of letermovir for prevention of CMV infections in patients with relapsed or refractory hematological malignancies, including CAR T cell recipients, should be determined in future trials.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Use in Patients with Relapsed or Refractory Hematological Malignancies () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2159;
The use of letermovir for prevention of CMV infections in patients with relapsed or refractory hematological malignancies, including CAR T cell recipients, should be determined in future trials. The use of letermovir for prevention of CMV infections in patients with relapsed or refractory hematological malignancies, including CAR T cell recipients, should be determined in future trials.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Use in Patients with Relapsed or Refractory Hematological Malignancies () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2158;
The use of letermovir for prevention of CMV infections in patients with relapsed or refractory hematological malignancies, including CAR T cell recipients, should be determined in future trials. The use of letermovir for prevention of CMV infections in patients with relapsed or refractory hematological malignancies, including CAR T cell recipients, should be determined in future trials.
- tacrolimus / Generic mfg.
[VIRTUAL] Decreased Incidence of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide in HLA-Matched Allogeneic Hematopoietic Cell Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1597;
At our institution, standard GVHD prophylaxis in reduced intensity (RIC) HLA-matched transplant has historically been a calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF)...Fifty-two patients underwent a RIC HLA-matched HCT with busulfan/fludarabine using PtCy, tacrolimus, and MMF GvHD prophylaxis between 4/2019-6/2020...CMV infections were not increased with PtCy, but this is confounded by the more recent use of letermovir prophylaxis...Longer-term data on these outcomes as well as impact on late effects are needed. As such, we eagerly await data from prospective randomized trials comparing PtCy and standard GVHD prophylaxis in RIC matched related donor transplants.
- tacrolimus / Generic mfg.
[VIRTUAL] Decreased Incidence of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide in HLA-Matched Allogeneic Hematopoietic Cell Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1596;
At our institution, standard GVHD prophylaxis in reduced intensity (RIC) HLA-matched transplant has historically been a calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF)...Fifty-two patients underwent a RIC HLA-matched HCT with busulfan/fludarabine using PtCy, tacrolimus, and MMF GvHD prophylaxis between 4/2019-6/2020...CMV infections were not increased with PtCy, but this is confounded by the more recent use of letermovir prophylaxis...Longer-term data on these outcomes as well as impact on late effects are needed. As such, we eagerly await data from prospective randomized trials comparing PtCy and standard GVHD prophylaxis in RIC matched related donor transplants.
- tacrolimus / Generic mfg.
[VIRTUAL] Decreased Incidence of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide in HLA-Matched Allogeneic Hematopoietic Cell Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1595;
At our institution, standard GVHD prophylaxis in reduced intensity (RIC) HLA-matched transplant has historically been a calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF)...Fifty-two patients underwent a RIC HLA-matched HCT with busulfan/fludarabine using PtCy, tacrolimus, and MMF GvHD prophylaxis between 4/2019-6/2020...CMV infections were not increased with PtCy, but this is confounded by the more recent use of letermovir prophylaxis...Longer-term data on these outcomes as well as impact on late effects are needed. As such, we eagerly await data from prospective randomized trials comparing PtCy and standard GVHD prophylaxis in RIC matched related donor transplants.
- tacrolimus / Generic mfg.
[VIRTUAL] Decreased Incidence of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide in HLA-Matched Allogeneic Hematopoietic Cell Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1594;
At our institution, standard GVHD prophylaxis in reduced intensity (RIC) HLA-matched transplant has historically been a calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF)...Fifty-two patients underwent a RIC HLA-matched HCT with busulfan/fludarabine using PtCy, tacrolimus, and MMF GvHD prophylaxis between 4/2019-6/2020...CMV infections were not increased with PtCy, but this is confounded by the more recent use of letermovir prophylaxis...Longer-term data on these outcomes as well as impact on late effects are needed. As such, we eagerly await data from prospective randomized trials comparing PtCy and standard GVHD prophylaxis in RIC matched related donor transplants.
- tacrolimus / Generic mfg.
[VIRTUAL] Decreased Incidence of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide in HLA-Matched Allogeneic Hematopoietic Cell Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1593;
At our institution, standard GVHD prophylaxis in reduced intensity (RIC) HLA-matched transplant has historically been a calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF)...Fifty-two patients underwent a RIC HLA-matched HCT with busulfan/fludarabine using PtCy, tacrolimus, and MMF GvHD prophylaxis between 4/2019-6/2020...CMV infections were not increased with PtCy, but this is confounded by the more recent use of letermovir prophylaxis...Longer-term data on these outcomes as well as impact on late effects are needed. As such, we eagerly await data from prospective randomized trials comparing PtCy and standard GVHD prophylaxis in RIC matched related donor transplants.